Fig. 6

IL1RAP as therapeutic target. A IL1RAP expression in BM CD34-, MNC, CD34 + sorted population. B Schematic representation of internalization assay. OCI-AML3 cells were stained with PE-conjugated IL1RAP antibodies at t = 0 min and incubated at 37 °C for indicated times. At t = 15 and 30 min, cells are stained with APC-conjugated anti-PE antibodies. Upon IL1RAP and PE-conjugated IL1RAP antibody internalization, APC signal should decrease with time while PE signal should remain constant. C Flow cytometry analysis of OCI-AML3 cells at different time points during internalization assay. P values were calculated using the Wilcoxon test. D Flow cytometry profile of anti-IL1RAP and anti-PE at different time point. E Growth inhibition assay with AML5 treated with Nadunolimab with PNU-conjugated secondary antibody (n = 2), PNU (n = 2), IgG contro l(n = 2), secondary antibody only (n = 1)